Vogenx, Inc. VOGX
Vogenx, Inc. (Nasdaq: VOGX) is an endocrine/women's health drug developer. Its lead program, mizagliflozin, is in Phase 2 for Post-bariatric hypoglycemia (PBH). Its next catalyst on record is mizagliflozin (PBH): Begin patient screening in Phase 2b EMERGE study (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: mizagliflozin (PBH) — Begin patient screening in Phase 2b EMERGE study (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| mizagliflozin | post-bariatric hypoglycemia (two Phase 2 studies completed; Phase 2b EMERGE in start-up) | small molecule | Phase 2 |
| mizagliflozin | gastroparesis (Phase 2 proof-of-concept planned) | small molecule | Pre-clinical |
| mizagliflozin | GIP-dependent Cushing's syndrome | small molecule | Pre-clinical |
| VGX-2857 | weight maintenance (considered) | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 endocrine/women's health companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.